Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01505530 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
NCT01505530: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT01505530 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 125 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01505530, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
Study Summary
This phase 2 study is a multicenter, randomized, double-blind, placebo-controlled trial in participants with locally advanced/inoperable or metastatic pancreatic cancer, and will investigate 2 different doses of LY2495655 in combination with standard of care chemotherapy.
Primary Outcome
Overall survival (OS) duration was measured from the date of randomization to the date of death from any cause.
Interventions
- DRUG Placebo
- DRUG Standard of Care Chemotherapy
- DRUG LY2495655
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2011-12 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
What the finished NCT01505530 record still lists
NCT01505530 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01505530 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01505530 about?
NCT01505530 is a clinical study titled "A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer". This phase 2 study is a multicenter, randomized, double-blind, placebo-controlled trial in participants with locally advanced/inoperable or metastatic pancreatic cancer, and will investigate 2 different doses of LY2495655 in combination with standard of care chemotherapy.
What is the current status of trial NCT01505530?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2011-12. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01505530?
The interventions under investigation include: Placebo (DRUG), Standard of Care Chemotherapy (DRUG), LY2495655 (DRUG).
Who is sponsoring clinical trial NCT01505530?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01505530's enrollment target sits among peer trials
125 558th of 2000 higher than 1,437 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia